The N-end rule relates the amino terminus to the rate of degradation through the ubiquitin/26 S proteasome pathway. Proteins bearing basic (type 1) or large hydrophobic (type 2) amino termini are assumed to be targeted through this pathway by their higher affinity for binding to the responsible E3 ligase compared with proteins bearing other residues (type 3). Paradoxically, a significant fraction of eukaryotic protein degradation occurs through the N-end rule pathway, although the majority of cellular proteins are type 3 substrates. We have exploited specific interactions between ubiquitin carrier proteins (E2/Ubc) and their cognate E3 ligases to purify for the first time the mammalian N-end rule ligase E3␣/Ubr1 to near homogeneity. In vitro studies show that E3␣ forms lysine 48-linked polyubiquitin degradation signals on type 1-3 substrates and is absolutely dependent on Ubc2/Rad6 orthologs. Biochemically defined kinetic studies show that the basis of N-end rule specificity is a k cat rather than the K m effect originally proposed, since all three substrate classes show similar binding affinities (K m ϳ5 M) but V max values that are 100-and 50-fold greater for type 1 and 2 versus type 3 model substrates, respectively. In addition, the N-end rule dipeptides lysylalanine and phenylalanylalanine are general noncompetitive inhibitors for E3␣-catalyzed ubiquitination of type 1-3 substrates rather than typespecific competitive inhibitors as predicted. These observations are consistent with a model in which the N-end rule effect reflects substrate binding-induced transitions in E3␣ to a catalytically competent conformer, the equilibrium for which depends on the identity of the amino terminus or the presence of basic or hydrophobic surface features. The model reconciles conflicts between specific predictions and empirical observations relating N-end rule targeting in addition to explicating the efficacy of selected dipeptides as potent in vivo inhibitors of this pathway.
A substantial body of evidence over the last 20 years firmly establishes ubiquitin/26 S proteasome-dependent degradation as the major pathway for the constitutive and the conditionally accelerated turnover of eukaryotic proteins, as recently reviewed (1, 2) . Although this pathway also functions in the degradation of long lived proteins, most recent attention has focused on the regulated degradation of short lived proteins that includes cyclins, transcription factors, p53, IB, plasma membrane proteins, and misfolded secretory proteins (1) . The defining feature of this pathway is the unique targeting of proteins for destruction by the assembly of a polyubiquitin degradation signal on surface-exposed lysine resides that is subsequently recognized by a subunit(s) of the 19 S regulatory complex within the 26 S proteasome (3) . Polyubiquitin chains are formed on the target protein by the processive conjugation of the carboxyl terminus of the 8.6-kDa polypeptide ubiquitin to lysine 48 of the adjacent ubiquitin moiety (4), although chains with alternative linkages to lysine 6 and lysine 11 serve as less abundant degradation signals (5, 6) .
The mechanism for ubiquitin conjugation minimally requires three classes of enzymes (7) . A ubiquitin-activating enzyme (E1) 1 catalyzes the ATP-coupled activation of the carboxyl terminus of ubiquitin to yield a ternary complex composed of two forms of activated ubiquitin: a tightly bound ubiquitin adenylate that serves as the precursor for a covalent ubiquitin thiolester to a conserved cysteine residue within E1 (8, 9) . The E1-bound ubiquitin thiolester is transferred to members of a superfamily of ubiquitin carrier proteins (E2) to form an E2-ubiquitin thiolester to a cysteine within a highly conserved core catalytic domain of ϳ150 amino acids that defines the class (10) . 2 Ubiquitin-target protein isopeptide bond formation is catalyzed by E2 family-specific isopeptide ligases (E3) that confer substrate selectivity (2, 7, 10) .
In targeting for 26 S proteasome-dependent degradation, the conflicting requirements of global specificity within the context of precise temporal and functional regulation have been satisfied in eukaryotes by the evolution of a hierarchical family of parallel ligation pathways possessing defined specificities for cognate E2-E3 pairs (10) . These divergent ligation pathways exhibit considerable diversity in their mechanisms by which target protein specificity is achieved. The SCF family of ligases are multimeric complexes composed minimally of Cdc53/Cullin1 and Skp1 to which substrates are recruited for ligation by their binding to adapter proteins containing F-box motifs that directly interact with Skp1 (11) (12) (13) (14) . Combinatorial specificity through the F-box proteins provides targeting of the cyclin-dependent kinase Sic1 by Cdc4 (11, 12, 14) , the G 1 cyclin by Grr1 (15) , and the Met-4 transcription factor of methionine biosynthesis by Met-30 (16 -18) , among a growing list of examples (7, 19) . In contrast, a second targeting pathway achieves substrate specificity through a family of distinct ligases that are defined by the presence of a conserved ϳ250-residue Hect (homologous to E6 carboxyl terminus) domain that appears to serve as a binding site for cognate Ubc4/5 or HsUbc7 3 isoforms (20, 21) and that also contains a cysteine required for forming a ligaseubiquitin thiolester intermediate (20) . Most recently, Weissman and colleagues (22) have identified the Ring H2 finger as a motif that appears to function as a general structural domain for E2 binding. Subsequent sequence analysis suggests that the U box may serve as a structurally related Ring H2 finger-like E2 interaction domain (23) .
The simplest of the ligation pathways characterized to date is that required in N-end rule targeting. This ubiquitin conjugation pathway is responsible for the bulk of constitutive protein degradation in several cell types (24 -26) , degradation of cellular proteins during developmentally programmed cell death within the intersegmental muscles of Manduca sexta (27) , and experimentally induced myofibrillar protein degradation in mammalian skeletal muscle (28 -30) . Genetic studies in yeast by Varshavsky and co-workers (24, 31) as well as in vitro work with rabbit reticulocyte extracts by Hershko and others (32, 33) have established the essential features of target protein specificity mediated by this pathway. The yeast N-end rule ligase Ubr1 (34) and its mammalian ortholog E3␣ (26, 35) display a marked selectivity for substrates bearing basic or large hydrophobic amino acid residues at the N terminus of protein targets. Amino terminal specificity is assumed to derive from affinity preferences for N-end rule versus non-N-end rule substrates, based on selective inhibition by dipeptides (26, 32, 36) , although this hypothesis has not been directly tested. As has been pointed out previously (24) , the majority of cytosolic proteins possess amino termini that are stabilizing within the empirical N-end rule predictions; therefore, it is difficult to reconcile the broad substrate specificity of this ligation pathway with the experimental results without invoking a role for endopeptidases in exposing internal destabilizing N-end rule residues or remodeling of the amino terminus by post-translational events (37) .
The inability to obtain sufficiently homogeneous preparations of Ubr1/E3␣ has hampered defined enzymological studies of the E2 and substrate specificity exhibited by the ligase. Affinity columns containing N-end rule substrates have provided modest levels of E3␣ purification (26) ; however, the absence of additional ligases or required subunits has not been well documented, and the use of unresolved mixtures of E2 isozymes fails to preclude contributions from other conjugation pathways in these early studies (26) . Recognition that the large number of E2/Ubc isozymes identified to date segregate into discrete families exhibiting distinct phenotypes (10) suggested to us that these proteins could be exploited as affinity ligands for the facile isolation of specific ligases or ligase families. We demonstrate here that ligand affinity columns containing E2 14k /HsUbc2 specifically bind E3␣ that can be subsequently eluted with sufficient purity to allow detailed kinetic characterization in biochemically defined rate assays. The results of these kinetic studies with model N-end rule and non-N-end rule substrates challenge current hypotheses for the mechanistic basis underlying the N-end rule effect.
MATERIALS AND METHODS
Bovine ubiquitin, creatine phosphokinase, yeast inorganic pyrophosphatase, yeast hexokinase, human ␣-lactalbumin, human ␤-lactoglobulin, and RNase S were purchased from Sigma. The ubiquitin was further purified to apparent homogeneity (5) then radioiodinated by the Chloramine T procedure (38) . A portion of the radiolabeled ubiquitin was used for the preparation of reductively methylated ubiquitin (39) . Carrier-free Na[ 125 I] and [2,8- 3 H]ATP were purchased from PerkinElmer Life Sciences. Rabbit liver E1 was purified to apparent homogeneity by adapting previous affinity chromatography and FPLC methods (40) and then quantitated by 125 I-ubiquitin thiolester assay and confirmed by the stoichiometric formation of ubiquitin [ 3 H]adenylate (8, 9) . Human/rabbit recombinant HsUbc2b/E2 14kb 4 (41) was expressed in Escherichia coli harboring pGEX-HsUbc2b as an aminoterminal GST fusion. Following purification by glutathione affinity chromatography, the GST moiety was cleaved with thrombin and the HsUbc2b purified to apparent homogeneity by Mono Q FPLC (40) . Recombinant HsUbc2b was quantitated by the E1-catalyzed stoichiometric formation of the corresponding 125 I-ubiquitin thiolester (40) , for which greater than 90% was active when compared with that predicted from an empirical ⑀ 280 for the polypeptide. The active site mutants HsUbc2C88A and HsUbc2C88S were generated by overlap extension polymerase chain reaction (42) and then expressed and purified identically to wild type protein. Processed recombinant HsUbc2C88S was quantitated by the E1-catalyzed stoichiometric formation of 125 I-ubiquitin oxyester. Since HsUbc2C88A is incapable of forming the corresponding ubiquitin thiolester, concentrations of this protein were estimated spectrophotometrically. Recombinant HsUbc2C88A or HsUbc2C88S was coupled to Affi-Gel 10 as described previously for the preparation of ubiquitin Affi-Gel 10 (8) to yield a concentration of 1 mg/ml bed volume (58 M).
Preparation of Rabbit Liver Fraction II-Liver Fraction II was prepared by a modification of previous methods (40, 43) . Adult male New Zealand rabbits were sacrificed by intravenous injection of pentobarbital. Livers averaging 80 g, wet weight, were immediately removed and placed in ice-cold 25 mM phosphate-buffered saline (pH 7.4). All subsequent steps were conducted at 4°C. Livers were minced and added to three volumes of 50 mM Tris-HCl (pH 7.5) containing 0.25 M sucrose, 5 mM EDTA, and 1 mM DTT and then lysed in a Waring blender by four 15-s pulses at the high speed setting. The homogenate was allowed to stand on ice 30 min and then filtered through cheese cloth to remove large debris. The resulting filtrate was centrifuged at 8000 ϫ g for 20 min to pellet cellular debris, and then the supernatant was centrifuged an additional 90 min at 10 5 ϫ g. Postribosomal supernatant equivalent to one liver was added to 600 ml of a 50% (v/v) slurry of DEAE-52 (Whatman) equilibrated in 50 mM Tris-HCl (pH 7.5) containing 1 mM DTT and stirred gently in the cold for 1 h. The slurry was washed on a Buchner funnel with 3 bed volumes of 50 mM Tris-HCl (pH 7.5) and 1 mM DTT and then eluted with 2 bed volumes of 50 mM Tris-HCl (pH 7.5) containing 1 mM DTT and 0.5 M NaCl. The resulting eluate was adjusted to 85% saturated ammonium sulfate and stirred for 4 h and then centrifuged at 8000 ϫ g for 30 min to pellet precipitated protein. Protein pellets were suspended in 30 ml of 50 mM Tris-HCl (pH 7.5) and 1 mM DTT per liver equivalent and then dialyzed overnight against 2 ϫ 4 liters of the same using 12-kDa exclusion limit dialysis tubing. Liver fraction II was divided into aliquots corresponding to one liver and stored at Ϫ80°C. Ligase activity was stable to storage under these conditions for at least 1 year.
125
I-Ubiquitin Conjugation Assays-Initial rates of 125 I-ubiquitin conjugation were measured at 37°C by an adaptation of earlier methods (38) . Reactions of 50-l final volume contained 50 mM Tris-HCl (pH 7.5), 2 mM ATP, 10 mM MgCl 2 , 10 mM creatine phosphate, 1 mM DTT, 1 IU/ml creatine phosphokinase, 1 IU/ml HPLC-purified yeast inorganic pyrophosphatase, and the indicated concentrations of target protein substrate, affinity-purified rabbit liver E1, recombinant rabbit/human HsUbc2b, and E3␣ or rabbit liver extract. Reactions were initiated by the addition of 125 I-ubiquitin (ϳ10 4 cpm/pmol) to a final concentration of 5 M. Incubations were quenched at the indicated times by the addition of 50 l of SDS sample buffer, boiled for 5 min, and then resolved by 12% (w/v) SDS-PAGE. The resulting gels were dried and then autoradiographed before determining the absolute amount of conjugated 125 I-ubiquitin formed by cutting the lanes from the dried gel and ␥-counting (38) . Control experiments were conducted to confirm that rates of conjugation were linear over the times of the incubations and were E3␣-limiting, demonstrated by the independence of initial rate on E1 and HsUbc2b concentrations (not shown). One unit of E3␣ activity was defined as the quantity of enzyme catalyzing an initial rate of 1 pmol/min of total 125 I-ubiquitin conjugation under the above conditions.
Other Procedures-Yeast inorganic pyrophosphatase routinely contained a protease activity that inactivated E1; therefore, the commercial enzyme was further purified by dissolving the lyophilized sample in 50 mM Tris-HCl (pH 7.5) containing 1 mM DTT and applying to a Mono Q HR 5/10 anion exchange column at a flow rate of 1 ml/min. The enzyme was eluted from the column as a symmetric peak using a linear 0 -0.5 M NaCl gradient (12.5 mM/min). Fractions containing pyrophosphatase activity were pooled and further resolved on a HR 10/30 Superose 12 gel filtration column equilibrated with 50 mM Tris-HCl (pH 7.5) containing 50 mM NaCl and 1 mM DTT at a flow rate of 1 ml/min. The resulting pyrophosphatase was apparently homogeneous by SDS-PAGE and was stored in aliquots at Ϫ80°C. Human ␣-lactalbumin was purified in a similar fashion, except that the apparently homogeneous protein eluted from the Mono Q column at 0.18 M NaCl and DTT was omitted from all buffers to preserve internal disulfide bonds. Fractions containing ␣-lactalbumin were pooled and resolved on an HR10/30 Superdex 75 column equilibrated in 50 mM Tris-HCl (pH 7.5) containing 50 mM NaCl. Commercial ␤-lactoglobulin and RNase S were purified to apparent homogeneity by adaptation of published methods (44, 45) .
RESULTS
Affinity Isolation of Rabbit Liver E3␣-To test the ability of ubiquitin carrier proteins to serve as facile affinity ligands, recombinant HsUbc2C88S was coupled to Affi-Gel 10 at a final concentration of 1 mg/ml bed volume (58 M). The C88S active site mutant was chosen over wild type HsUbc2b to obviate potential false positive results arising from disulfide bond formation between cysteine 88 of the E2 and thiol groups that might be present on the ligase. When rabbit liver fraction II was passed through the affinity column in the absence of ATP, 98% of the initial 125 I-ubiquitin conjugating activity was absent from the unadsorbed fraction (Fig. 1A) . Even after passage of 6 bed volumes of fraction II through the column, residual activity in the unadsorbed fraction represented only 3% of the initial conjugating activity.
Loss of conjugating activity from the unadsorbed fraction of the HsUbc2C88S Affi-Gel 10 column did not result from retention of endogenous E1 or HsUbc2 by the affinity column, since supplementing the unadsorbed fraction with exogenous activating enzyme and/or carrier protein failed to restore activity (not shown). These results suggested that E3␣ was specifically bound to the HsUbc2C88S affinity column. Following removal of nonspecifically bound protein by washing the column with 2 bed volumes of 50 mM Tris-HCl (pH 7.5) containing 20 mM NaCl and 1 mM DTT, during which no detectable conjugating activity was eluted, specifically column-bound protein was eluted with 1 M NaCl in 50 mM Tris-HCl (pH 7.5) and 1 mM DTT. A quantitative assay of conjugating activity is difficult under these conditions, since the collection of potential ligation substrates present in the wash and eluate fractions differs significantly from that present in the starting fraction; moreover, exogenous model substrates fail to replicate the rates observed with natural substrates. Therefore, ligase activity was measured in complementation assays containing volume-normalized aliquots of wash or eluate and unadsorbed fraction II (to provide substrate proteins) as described in the legend to Fig. 1 . The complementation assays revealed that conjugating activity was eluted from the HsUbc2C88S affinity column by 1 M NaCl (Fig. 1A) . When eluate fractions were pooled and directly assayed, ϳ60% of the starting conjugating activity was consistently observed. Subsequent studies showed that the ligation reaction is partially inhibited by high NaCl concentration present in the eluate fractions. Following dialysis, greater than 90% of the starting conjugating activity was consistently observed in the pooled eluate when quantitated in the complementation assay. Protein determinations of fraction II (1138 mg) and the affinity eluate (2.8 mg) showed that the affinity step afforded an ϳ400-fold purification. The dialyzed affinity eluate corresponded to 5.3 ϫ 10 4 units of total activity (defined under "Materials and Methods" for the reconstitution assay) with a specific activity of 1.9 ϫ 10 4 units/mg protein. Resolution of volume-normalized samples of starting fraction II and pooled eluate by 10% SDS-PAGE followed by silver staining (46) failed to show any detectable protein in the latter sample; however, when starting fraction II was compared with pooled eluate representing 30 times the corresponding volume- normalized amount, prominent protein bands at 190, 116, and 56 kDa were observed in addition to several other minor bands of intermediate molecular weight (Fig. 1B) . Partial amino-terminal sequencing of the 116-kDa band revealed this protein to be 10-formyl tetrahydrofolate dehydrogenase, an abundant enzyme of one carbon metabolism that constitutes ϳ5-10% of total protein in rodent liver (47, 48) . Further studies with an authentic sample of 10-formyl tetrahydrofolate dehydrogenase failed to show ligase activity in assays supplemented with E1 and HsUbc2b; nor did it enhance the ligase activity of E3␣ (not shown). Therefore, the presence of 10-formyl tetrahydrofolate dehydrogenase in the affinity-purified ligase eluate probably reflects its binding to E3␣, although the enzyme contains a type 3 non-N-end rule amino terminus (48, 49) .
When assays were conducted on the pooled eluate using the N-end rule substrate human ␣-lactalbumin, a ladder of 125 Ipolyubiquitin adducts was observed following SDS-PAGE resolution and autoradiography that corresponded in mobility to that expected for the incremental increase in relative molecular weight upon the addition of successive ubiquitin moieties (Fig. 2, left panel) . This conclusion was confirmed by formation of a ladder of identical mobilities when 125 I-␣-lactalbumin and unlabeled ubiquitin were substituted in a parallel incubation (not shown). In addition, only monoubiquitinated ␣-lactalbumin was formed when either reductively methylated 125 I-ubiquitin or 125 I-UbK48R was substituted for the wild type radioiodinated polypeptide (not shown), indicating that the polyubiquitin chains are uniformly linked through lysine 48 of ubiquitin (5, 39) . In contrast, no conjugates were observed in the absence of added substrate protein, demonstrating the requirement for exogenous substrate. Finally, the E3␣ preparation was devoid of ubiquitin isopeptidase and unrelated protease activities, since 125 I-polyubiquitin conjugates were stable for several hours following ATP depletion (not shown).
The initial conjugation of 125 I-ubiquitin and subsequent polyubiquitin chain formation was absolutely dependent on the addition of E1 (not shown) and HsUbc2b (Fig. 2, right panel) , indicating that neither the activating enzyme nor carrier protein was present in the eluate. This conclusion was confirmed in separate 125 I-ubiquitin thiolester assays of the pooled eluate, which failed to reveal detectable levels of either E1 or E2 thiolester adducts (not shown). In addition, other studies (Fig.  2, right panel) showed that 125 I-ubiquitin conjugation/chain formation was absolutely dependent on the addition of Ubc2 family members, since 1 M HsUbc2b or its yeast ortholog ScUbc2/Rad6 supported E3␣-dependent conjugation but not equivalent concentrations (quantitated by separate 125 I-ubiquitin thiolester activity assays) of purified recombinant HsUbc3 (ortholog of Saccharomyces cerevisiae ScUbc3/Cdc34), 5 HsUbc5A/B/C (shown in Fig. 2 only for the HsUbc5A/UbcH5A isoform), HsUbc7A/OcE2-F1, HsE2 EPF (not shown), or any of the E2 isozymes found in rabbit reticulocyte extracts (not shown). Synergistic contributions or competitive binding by these other E2 isoforms were ruled out by the observation that the rates of total E3␣-catalyzed ubiquitin conjugation (initial and chain formation) were unaffected when a 1 M concentration of the previously listed E2 species was included with either 0.25 or 1 M of HsUbc2b (not shown).
The concentrations of E1 and HsUbc2b employed in the incubations of Fig. 2 were chosen empirically in preliminary experiments to yield rates of total 125 I-ubiquitin conjugation to human ␣-lactalbumin, determined by excising the upper portions of the lanes and quantitating associated ␥ radioactivity (38) , that were linear with respect to time and E3␣ concentration but independent of [E1] o and [HsUbc2b] o . Therefore, the relative autoradiographic intensities of individual polyubiquitin bands represent steady state levels of the individual species defined by the relative rates for the addition of n versus n ϩ 1 ubiquitin moieties. Highly processive ubiquitin chain elongation is shown by the virtual absence of an ␣-lactalbuminUb 1 band (Fig. 2) , although this species is the only ligation product in the presence of either reductively methylated 125 Iubiquitin or 125 I-UbK48R (not shown). Similarly, the lower autoradiographic intensity of the -Ub 4 band relative to its -Ub 3 precursor or -Ub 5 product indicates that the steady state rate for subsequent conjugation of the tetraubiquitin adduct is more rapid than its rate of formation, providing insights into the relative rates of individual steps in the chain elongation reaction.
In other studies, we found that recombinant HsUbc2C88A mutant could substitute for HsUbc2C88S with equal efficiency in binding conjugating activity from the starting fraction and in the excellent recovery of such activity following 1 M NaCl elution. Diminished binding of conjugating activity was observed with columns containing lower concentrations of either HsUbc2 active site mutant, extensive use of the column, or following prolonged storage. These observations suggest that efficient binding of conjugating activity is acutely sensitive to ligand concentration and that repeated use of the columns or prolonged storage results in denaturation and/or degradation of the column-bound E2 ligand, resulting in ablated E3␣ binding. 5 The series of closely spaced conjugate bands in Fig. 2 (right panel) that is seen in the presence of HsUbc3 represents the E3-independent autoubiquitination products typical of this isoform (39). (Fig. 3A) , corresponding to the presence of the 190-kDa band when further analyzed by SDS-PAGE (Fig. 3B) . That the 190-kDa protein band represents the ligase was confirmed by the constant specific activity across the peak when conjugating activity was normalized to 190-kDa band density (Fig. 3C, open  circles) . A slightly higher relative molecular mass band coeluted with the 190-kDa E3␣ species (Fig. 3B) . We cannot distinguish whether the larger band represents the authentic full-length E3␣, a co-eluting substrate, or another Ubc2-binding protein. However, constant relative specific activity when normalized instead to this higher molecular weight band (Fig.  3C, closed circles) argues that the protein does not differ significantly in activity from the lower band (if the full-length E3␣), does not compete for exogenous substrate (if a co-eluting substrate), or does not show ligase activity (if a distinct Ubc2-binding ligase). We have also resolved the pooled affinity eluate by glycerol gradient centrifugation and observed a single peak of HsUbc2b-dependent 125 I-ubiquitin conjugating activity having a relative molecular mass of ϳ200 kDa and constant specific activity when analyzed similar to Fig. 3 , B and C (not shown). For Superose 12 gel exclusion chromatography and glycerol gradient centrifugation, as well as Mono Q anion exchange FPLC (not shown), HsUbc2b-dependent lysine 48-linked polyubiquitin chain formation to human ␣-lactalbumin consistently co-eluted with the ϳ190-kDa band. Therefore, chain formation appears to be an intrinsic catalytic property of E3␣. We also observed robust lysine 48-linked chain formation with human E3␣ purified to apparent homogeneity (Ͼ99%) from outdated human erythrocytes, again supporting the hypothesis that cognate chain formation is an integral catalytic feature of HsUbc2-E3␣/Ubr1.
The good correspondence between the native molecular mass of ϳ190 kDa for the HsUbc2-dependent ligase by gel exclusion chromatography (Fig. 3) and glycerol gradient centrifugation with the reported molecular mass of 189 kDa for E3␣ (26) in addition to the absolute dependence of conjugating activity on orthologs of the Ubc2 family support the identity of the activity as the ligase required for N-end rule-dependent targeting. The previous results show that the HsUbc2-ligand affinity method is capable of quantitatively resolving E3␣ activity from a complex mixture of proteins present in liver fraction II in a single step; however, also eluted are a small subset of cellular proteins presumably representing tightly bound ligase substrates, by analogy with the presence of 10-formyl tetrahydrofolate dehydrogenase. This latter property of E3␣ probably accounts for previous difficulties in purifying the enzyme by conventional chromatographic methods.
The N-end Rule Is a V max Effect-Specificity within the Nend rule targeting pathway is assumed to arise from differences in binding affinity between E3␣/Ubr1 and proteins bearing different classes of destabilizing residues at their amino termini (24, 26, 50) . The availability of highly purified E3␣ in the present studies allowed us kinetically to test this assumption in biochemically defined ligation reactions, obviating potential contributions from other pathways or components present within intact cells or cell extracts used in previous studies. Initial rates for the monoubiquitination of three model protein substrates used previously to demonstrate qualitative selectivity by the N-end rule pathway (26, 50) were examined using reductively methylated 125 I-ubiquitin, as described under "Materials and Methods." Human ␣-lactalbumin is an N-end rule substrate possessing a type 1 destabilizing lysine residue at its amino terminus, while human ␤-lactoglobulin is a type 2 N-end rule substrate having a destabilizing phenylalanine amino terminus (51) . In contrast, the subtilisn-derived fragment of ribonuclease A, RNase S, bears a stabilizing serine amino terminus and is thus predicted by the N-end rule to show a significantly lower affinity for binding to E3␣ (51) .
Rates for the initial monoubiquitination of the three target proteins were measured using reductively methylated 125 Iubiquitin, which is incapable of supporting subsequent chain elongation but which is otherwise functionally identical to wild type polypeptide (39) . Initial rates for monoubiquitination rather than total chain formation were chosen for study, since the former should more closely reflect substrate recognition events mediated by E3␣. The dependence of initial rates for monoubiquitination on the concentrations of the three model substrates yielded hyperbolic kinetics, demonstrated by the linearity of the data when analyzed by a double reciprocal plot (Fig. 4) . As is readily apparent from Fig. 4 , all three substrates possess similar affinities for binding to E3␣ (Table I) , contrary to the predictions of the N-end rule model.
In contrast, the data of Fig. 4 and Table I reveal that specificity within this targeting pathway reflects a significant V max effect for N-end rule (types 1 and 2 substrates) versus non-Nend rule (type 3) substrates. Human ␣-lactalbumin and ␤-lactoglobulin, both of which possess destabilizing amino-terminal residues, show nearly identical V max values of 0.58 Ϯ 0.05 and 0.22 Ϯ 0.02 pmol/min, respectively, in parallel assays while RNase S displays a 100-fold lower V max of 0.005 Ϯ 0.001 pmol/ min (note difference in y axis scale for RNase S). The results of Fig. 4 and Table I were observed with several different preparations of the three model substrates and, therefore, do not reflect potential differences in the fraction of native protein present. In addition, qualitatively similar results were observed when initial rates for conjugation of unlabeled reductively methylated ubiquitin were measured using radiolabeled substrates, although K m values determined with these substrates were 2-4-fold higher than with unlabeled substrate proteins (not shown). Nonetheless, the overall trend evident in Fig. 4 and Table I was observed with radioiodinated target proteins. Finally, statistically similar K m , but correspondingly larger V max , values were obtained when rates were expressed as total ubiquitin conjugation (initial and chain formation) using wild type 125 I-ubiquitin (not shown). This agreement indicates that the addition of the first ubiquitin to the target protein is the rate-limiting step for E3␣-dependent conjugation.
The results of Fig. 4 and Table I are inconsistent with predictions implicit in the N-end rule hypothesis that target proteins bearing different amino termini should exhibit different affinities for binding to E3␣, reflected in the K m values for the respective model substrates (24) . The observation that the K m values for three model substrates, representing different classes of amino-terminal residues empirically defined by the N-end rule, are identical within the reproducibility of the rate measurements indicates that E3␣ shows relatively little discrimination in binding affinity. However, the significant range in V max values for the initial ubiquitination of the different substrate classes strongly supports an alternative interpretation that the N-end rule is a rate effect representing substrate-dependent differences in the catalytic competence of the ternary Michaelis complex composed of E3␣, substrate, and Ubc2-ubiquitin thiolester.
Dipeptide Inhibition of E3␣ Ligase Activity-A characteristic feature of E3␣-mediated conjugation is the reported selectivity of dipeptides in inhibiting ligase activity with a sequence specificity predicted by the N-end rule in vitro (50) and in vivo (36) . However, earlier studies have not addressed the technical problem that these dipeptides are also capable of acting as nucleophilic acceptors of activated ubiquitin present as high energy thiolester intermediates on E1 and E2 isozymes, resulting in nonspecific inhibition of E3␣-catalyzed ligation that would be independent of overt substrate specificity. Indeed, we observed that several dipeptides including lysylalanine (KA), alanyllysine (AK), arginylalanine, phenylalanylalanine (FA), and alanylphenylalanine were effective at millimolar concentrations in reducing the steady state level of 125 I-ubiquitin thiolester present within the E1 ternary complex (not shown). In the absence of rigorously defined kinetic conditions, inhibition of steady state E1-and Ubc2-ubiquitin thiolester levels could affect the observed rates of conjugation and be erroneously interpreted as a direct effect on E3␣ specificity. In biochemically defined rate assays such as those of Figs. 2 and 4 , however, sufficiently high concentrations of E1 and HsUbc2b could be empirically established to ensure E3␣-limiting conditions, obviating potential effects of the dipeptides on the steady state concentrations of thiolester intermediates. Fig. 5 illustrates the effect of selected dipeptides on the initial rates of conjugation to the radioiodinated forms of the three model substrates used in Fig. 4 . That the rates were limiting with respect to E3␣ at the highest concentrations of dipeptide tested were confirmed by the linearity of initial velocities on the concentration of ligase present in the assays and the independence of the rates on the concentrations of either E1 or HsUbc2b (not shown). The type 1 dipeptide KA showed the greatest inhibition on the initial velocities for ligation of all three substrate classes (Fig. 5) . In contrast, the effect of AK was observed only at the highest concentrations for 125 I-␣-lactalbumin but absent for 125 I-␤-lactoglobulin and 125 I-RNase S. In parallel experiments, the effects of arginylalanine and alanylarginine were qualitatively indistinguishable from those of KA and AK, respectively (not shown). The other three dipeptides tested showed the same rank order in efficacy for the three substrates. The slightly better inhibition of 125 I-␤-lactoglobulin ligation (type 2 substrate) by the type 2 dipeptide FA compared with alanylphenylalanine is qualitatively consistent with earlier reports (50) . However, the ability of KA efficiently to inhibit the type 2 substrate ␤-lactoglobulin and the type 3 substrate RNase S is contrary to published observations (50) FIG. 4. Concentration dependence for E3␣-catalyzed monoubiquitination. Concentration dependences on initial rates for the monoubiquitination of human ␣-lactalbumin (solid circles, left axis), human ␤-lactoglobulin (open circles, left axis), and bovine pancreatic RNase S (closed triangles, right axis) were measured in incubations containing 100 nM rabbit liver E1, 1 M recombinant HsUbc2b, and 1 g of E3␣ as described under "Materials and Methods" and then analyzed by double reciprocal plots. Lines through the data points represent theoretical nonlinear least squares fits for the kinetic parameters summarized in Table I . Note the 10-fold difference in magnitude between the left (␣-lactalbumin and ␤-lactoglobulin) and right (RNase S) axes. 
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and inconsistent with empirical predictions based on the N-end rule model (24) . Lysylalanine Is a Noncompetitive Inhibitor of E3␣-Dipeptide inhibition of N-end rule-dependent conjugation by E3␣/ Ubr1 is assumed to result from competition with their respective substrate types for binding to distinct sites on the ligase (50); however, this assumption has not been rigorously tested previously. Shown in Fig. 6 are the effects of various concentrations of KA on the initial rates of 125 I-␣-lactalbumin monoubiquitination with reductively methylated ubiquitin. The inhibition pattern displayed in Fig. 6 indicates that KA is a classic noncompetitive inhibitor of E3␣, since the dipeptide has no effect on the K m but results in a progressive, saturable decrease in the apparent V max with increasing concentration. Linearity of the secondary plot of 1/V mav versus KA concentration (Fig. 6,  inset) demonstrates that inhibition by the dipeptide requires binding to E3␣, with a K i of 6 mM. Parallel kinetic experiments demonstrated that KA was similarly a noncompetitive inhibitor of 125 I-␤-lactoglobulin and 125 I-RNase S monoubiquitination, yielding K i values of 3.2 and 26 mM, respectively (not shown). In addition, FA proved to be a noncompetitive inhibitor of 125 I-␤-lactoglobulin monoubiquitination, although with a corresponding K i of 25 mM (not shown). Therefore, both types 1 and 2 dipeptides show noncompetitive inhibition of N-end rule and non-N end rule substrate classes.
DISCUSSION
Segregation of the E2 ubiquitin carrier proteins into functionally distinct families (10) suggested to us that unique E2-E3 interactions could be exploited for the affinity purification of isozyme-specific ubiquitin ligases. In the present work, we have demonstrated that HsUbc2, the human/rabbit ortholog of S. cerevisiae Ubc2/Rad6, is an efficient and specific ligand for the facile and quantitative isolation of the cognate N-end rule ligase E3␣ (Fig. 1) , the mammalian ortholog of yeast Ubr1, to the exclusion of other E2-specific ligase families (Fig. 2) .
Like most other ubiquitin ligases, the Ubc2-dependent Ubr1 ligase responsible for N-end rule targeting is present in yeast as three closely related isoforms, based on their sequences, that have corresponding orthologs in murine and human systems (35) . Sequence comparison indicates that E3␣ corresponds to the mammalian ortholog of yeast Ubr1 (35) . The roles of the Ubr2 and Ubr3 isoforms are unknown, although one may correspond to the mammalian E3␤ activity identified by Heller and Hershko (52) . That the ligase activity isolated here is identical to E3␣ is supported by the good correspondence between the observed (Fig. 1B) and reported molecular mass of 189 kDa, the absolute dependence on Ubc2 orthologs for activity (Fig. 2) , the markedly enhanced conjugating activity toward type 1 and 2 N-end rule substrates (Fig. 4) , and the efficacy with which appropriate dipeptides are capable of inhibiting target protein conjugation (Fig. 5) . While we cannot absolutely preclude the presence of other HsUbc2-dependent ligases, the quantitative correspondence of the 190-kDa protein with ubiquitin conjugating activity and polyubiquitin chain formation through various chromatographic steps ( Fig. 3 and associated text) is consistent with a single activity. The availability of highly purified E3␣ apparently devoid of other contaminating ligases or isopeptidases has allowed us for the first time to exploit kinetic approaches in biochemically defined systems in order to test the current model for target protein specificity within the N-end rule pathway. Results of these studies demonstrate that ubiquitin conjugation is amenable to precise kinetic analysis, providing mechanistic insights inaccessible to other experimental approaches.
The kinetics of ubiquitin conjugation to three model substrates, employed previously to demonstrate N-end rule targeting in vitro, unambiguously demonstrate that N-end rule specificity is a rate (k cat ) rather than an affinity (K m ) effect (Fig. 4 and Table I ), contrary to the original interpretations based on biochemical (26, 50) and genetic observations (24) . Nearly identical affinities for binding of types 1-3 model substrates to E3␣, reflected in similar K m values of ϳ5 M ( Table I ), demonstrate that the N-end rule ligase has a relatively nonspecific polypeptide substrate binding site that does not discriminate among different amino-terminal residues. In contrast, the identity of the amino-terminal residue significantly affects the V max for E3␣-catalyzed conjugation of the initial ubiquitin to the target protein, the rate-limiting step for generating the polyubiquitin degradation signal that is recognized by the 26 S proteasome, Fig. 4 . Therefore, although E3␣ is capable of specifically interacting with different classes of amino-terminal residues, the strength of this interaction in isolation must be negligible compared with the overall substrate binding affinity reflected in the K m values (Table I) .
The clearest insight into the mechanism of E3␣ derives from the dipeptide inhibitor studies. Inhibition of conjugation rather than activation by the appropriate dipeptides rules out the amino-terminal interaction site(s) as a simple positive allosteric regulatory element, which is otherwise rare among monomeric enzymes such as E3␣. The positive V max effects observed with the type 1 and 2 model substrates (Fig. 4 and Table  I ), in contrast to the inhibition observed for the dipeptides (Fig.  5) , requires that substrate amino-terminal residues interacting with the amino-terminal interaction site(s) must be contiguous with the target protein. Such scenarios are relatively common among enzyme mechanisms for which substrate binding is accompanied by a conformational change leading to the catalytically competent Michaelis complex. In the present case, we propose a model whereby the enzyme (E3␣) exhibits selectivity toward one group on the substrate (the amino terminus) in inducing the conformational change leading to the catalytic step. The extent to which the amino-terminal residue is able to effect the optimal conformation of the Michaelis complex determines the magnitude of the k cat enhancement, accounting for the observed differences in V max among the three model substrates (Table I) .
The present observations are consistent with the minimum model summarized by Scheme 1, in which E3␣ is assumed to exist in two conformations, E and EЈ. The two conformers are shown in schematic diagram form below the scheme as their corresponding Michaelis complexes. In the latter representation, the amino-terminal interaction site(s) are assumed to engage the amino-terminal residue (black oval) of the substrate (square) only in the EЈ conformer. We propose that substrate binding is coupled to the E 3 EЈ transition and that EЈ is the catalytically competent conformer, requiring k cat Ј Ͼ k cat , consistent with the V max effect shown by N-end rule substrates. The scheme considers the possibility of product formation from ES, since the present data do not preclude a finite value for k cat ; however, since all three substrate types are inhibited by the KA dipeptide and the limiting velocity tends to zero (Fig. 5) , it is more likely that k cat Ϸ 0 in the absence of substrate bindinginduced conformational changes. In Scheme 1, the topological separation of the amino-terminal interaction site(s) from the substrate binding site and catalytic machinery, implicit in the model, is supported by previous studies with ubiquitin-␤-galactosidase fusion constructs by Varshavsky and co-workers (24, 31 6 Observation that the N-end rule effect is in V max (i.e. k cat ) restricts the distribution between the E and EЈ conformers to values of ␣Ј Ͼ ␣. The present data cannot distinguish whether binding of an N-end rule substrate induces the conformational change in the enzyme or stabilizes the more active EЈ conformer, since both interpretations are thermodynamically identical. However, microscopic reversibility and the corresponding restriction that ␣Ј Ͼ ␣ requires that KЈ m Ͻ K m for both models. The latter thermodynamic constraint probably accounts for the apparent higher affinity of mammalian E3␣ for binding to affinity columns containing types 1 or 2 substrates under equilibrium conditions (26, 32) and predicts similar behavior under solution equilibrium conditions; however, the apparent higher affinity is merely a consequence of substrate-specific differences in ␣Ј rather than intrinsic differences in K m (Scheme 1). Therefore, the difference in V max values among types 1 and 2 versus type 3 substrates reflects the extent to which their respective binding is capable of promoting formation of the EЈS conformer, that is, the relative values of ␣Ј for each substrate type. Within Scheme 1, inhibition by the appropriate dipeptides (Fig. 5 ) must occur through their competition with the substrate amino-terminal residue for interacting with the amino-terminal recognition site(s) to block the E 3 EЈ transition. However, because this conformer transition results in the observed V max effect, the dipeptides will appear to act as noncompetitive inhibitors (Fig. 6 and legend) . That KA and FA dipeptides effectively inhibit all three substrate types (Fig. 5) suggests that type 3 substrates are capable of inducing a small 6 The participation of Ubc2b-ubiquitin thiolester is omitted in Scheme 1 for clarity. but measurable conformational change (low ␣Ј value) and that the basic and hydrophobic amino-terminal interaction sites must overlap.
Recently, Turner and Varshavsky demonstrated in yeast that N-end rule dipeptides enhance the uptake from medium of dipeptides by stimulating Ubr1 targeting for degradation of Cup9, a transcriptional repressor of the peptide transporter Ptr2 (53, 54) . Dipeptide stimulation of Ubr1 conjugating activity is apparently independent of the inhibitory effects reported previously for such compounds, since the former occurs in the micromolar range (53, 54) , while inhibition is observed only at millimolar dipeptide concentrations (36) . Dipeptide simulation of the N-end rule targeting by Ubr1 may be specific to S. cerevisiae Cup9, since we have observed no similar stimulation of rabbit or human E3␣ conjugation rates with model substrates at micromolar dipeptide concentrations (not shown).
The present observations and the resulting kinetic model of Scheme 1 reconcile otherwise conflicting data concerning the specificity of the N-end rule pathway. We show that initial substrate binding is relatively nonspecific with regard to the identity of the amino-terminal residue for E3␣/Ubr1, the ubiquitin-protein ligase responsible for N-end rule targeting (Fig. 4 and Table I ). This explicates the apparent broad substrate specificity of the N-end rule pathway in basal cellular protein degradation (24 -26) , basal and atrophy-induced increases in degradation of muscle proteins (27, 55, 56) , and growth factorinduced neurite outgrowth (57, 58) . Instead, rates of ubiquitin conjugation, and hence subsequent degradation, depend on the efficacy with which formation of the Michaelis complex is coupled with transition to the catalytically-competent conformer (EЈ in Scheme 1). Substrates containing type 3 amino termini, constituting the majority of cellular proteins (37) , are apparently capable of modest substrate binding-induced conformational changes, as revealed by the dipeptide inhibition of ribonuclease S ligation (Fig. 4) . More effective conformational changes are afforded by proteins harboring amino-terminal type 1 or 2 residues, as originally envisioned by the N-end rule hypothesis (24, 31) . The minimal structural requirements for enhanced E3␣ targeting appear to be a basic or hydrophobic region within a defined distance from a sterically accessible lysine serving as the site for ligation (24, 31) .
The requirements of this bipartite targeting motif can apparently be satisfied by either amino-terminal or internal basic/hydrophobic interaction sites. The latter is illustrated by recent findings with 3C protease (59, 60) . Critical timing of viral polyprotein processing and virion assembly within the picornaviruses depends on E3␣-dependent degradation of the viral 3C protease, a type 3 non-N-end rule substrate (59, 60 ). An internal basic peptide sequence present on a solvent-exposed reverse turn of encephalomyocarditis virus 3C protease serves as a transferable degradation signal recognized by E3␣ (60) . Mutation of critical basic residues within this surfaceexposed degradation signal ablates the V max for E3␣-catalyzed ubiquitination of encephalomyocarditis virus 3C protease, as predicted by Scheme 1. Cognate dipeptide inhibitors are shown in the present study to function as noncompetitive inhibitors of types 1, 2, and 3 model substrates. Scheme 1 interprets such inhibition as uncoupling of the substrate-induced conformational change by competition between cognate dipeptides and basic or hydrophobic segment on the substrate protein for interaction with the complementary site on E3␣. This accounts for the apparent broad efficacy of dipeptide inhibitors in ablating E3␣-mediated muscle atrophy (27, 55, 56) and in blocking N-end rule-dependent neurite outgrowth (57, 58) . In addition, we have more recently found that suitable type 1 or 2 dipeptides also noncompetitively inhibit in vitro E3␣-catalyzed ubiquitination of encephalomyocarditis virus 3C protease, 7 consistent with the predictions of Scheme 1.
The present studies were prompted by our ability to obtain significant quantifies of highly purified E3␣ with which to conduct rigorous kinetic tests of N-end rule specificity. This technical advance exploits highly specific interactions between cognate E2-E3 pairs, predicted from phylogenetic analysis of E2/Ubc orthologs (10), providing a reproducible and facile means of isolating functional ubiquitin-protein ligases. Moreover, we have replicated these results with other families of E2 ligands, illustrating the general utility of the approach. Subsequent rate studies demonstrate that ubiquitin conjugation is amenable to defined enzymological study in order to provide mechanistic details not accessible by other approaches. Rather than refute the N-end rule, these observations codify previously disparate findings by demonstrating that targeting specificity is predicated on a k cat effect mediated by substrate binding-induced conformational changes in the responsible E3␣/ Ubr1 ligase. This finding expands the range of potential substrates sensitive to E3␣/Ubr1 targeting without invoking additional global post-translational modifications of substrate proteins through amino-terminal modification and/or endopro-teolytic cleavages to expose destabilizing residues. Most significant, the present findings provide a mechanistic rationale for exploring suitable low molecular weight cell permeable compounds as therapeutic agents specifically to target E3␣/Ubr1-mediated degradation.
